FDA022 Antibody Drug Conjugate

FDA022抗体偶联剂

Report date: 2026/05/06 20:02:28

Base Information

Drug NameFDA022 Antibody Drug Conjugate

Drug Alias NameFDA022-BB05F0034

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload > MAAA-1181a payload

Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I

Therapy Area/IndicationsSolid tumoursBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A